ANGPTL3 and generalized lipodystrophy: In humans, patients with generalized lipodystrophy receiving metreleptin replacement therapy exhibited a rapid decline in plasma ANGPTL3, consistent in direction with animal and cellular data and supporting negative regulation of hepatocyte ANGPTL3 by the energy/adipose-reserve–leptin axis (34).